ImmuCell Corporation — Q3 2011 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2011. Unaudited statements; comparisons are with the corresponding 2010 periods unless otherwise noted. ImmuCell develops and sells animal-health products for the dairy and beef industries.
Financial performance and position
| Metric | Q3 2011 | Nine months 2011 | Comparison |
|---|---|---|---|
| Product sales | $1.003 million | $3.807 million | Up 15% and 17%, respectively |
| Gross margin | $526,000; 52% | $2.089 million; 55% | 2010: $357,000; 41% and $1.715 million; 53% |
| Operating loss | $192,000 | $642,000 | 2010: $348,000 and $470,000 loss |
| Net loss | $128,000; $0.04 per share | $409,000; $0.14 per share | 2010: $197,000; $0.07 and $257,000; $0.09 loss |
| Operating cash flow | Not separately reported for the quarter | $(332,000) | $(387,000) in the 2010 nine-month period |
At September 30, cash and cash equivalents were $564,000 and short-term investments were $4.181 million, totaling $4.745 million, up $119,000 from year-end 2010. Working capital was $6.490 million. Total assets were $10.979 million; stockholders’ equity was $8.994 million.
Bank debt totaled approximately $1.483 million, comprising $171,000 current and $1.312 million long-term; the balance sheet also reports a $65,000 interest-rate-swap liability. The company must maintain at least $1 million of unrestricted cash, cash equivalents and short-term investments under its bank covenant. Management reported covenant compliance at quarter-end. The mortgage rate is fixed at 6.04% through a swap; the $600,000 note has a variable rate. Debt is secured by substantially all company assets.
Material changes and business developments
- Q3 sales growth was driven by a 19% increase in domestic sales; international sales declined 5%. Nine-month domestic and international sales rose 19% and 6%, respectively.
- First Defense sales rose 22% in Q3 and 26% year to date. Wipe Out Dairy Wipes sales fell 24% and 16%, respectively, with management citing price competition and the decline in smaller dairy farms.
- Management said timing of bulk reagent sales makes reported nine-month sales comparisons less direct: a similar reagent sale occurred in Q2 2010 and was expected in Q4 2011. Excluding those reagents, core animal-health sales increased 22% year to date.
- Two distributors represented 54% of nine-month sales and 45% of receivables at September 30, on a basis that reflects their acquisitions retroactively. U.S. dairy and beef customers accounted for 84% of nine-month sales.
- Product development expense increased 38% year to date to $1.449 million, principally for Mast Out manufacturing-process development and First Defense rotavirus studies. Sales and marketing expense rose 34% to $634,000, a planned investment that management believes may have contributed to sales growth.
Outlook, risks and unusual items
- Management expects higher product-development spending for full-year 2011, but says reducing Mast Out development spending could support a return to profitability. It gave no specific timing or quantified forecast for that return. Its stated indicators to monitor are gross margin, operating income or loss, and net income or loss.
- Mast Out requires approximately $6 million to $9 million of additional funding, principally for manufacturing scale-up and validation batches. ImmuCell is pursuing a partner; discussions were ongoing and timing or success was uncertain. Management believes existing resources are sufficient for working capital and operations for at least 12 months, but this does not resolve the separate Mast Out funding need.
- Mast Out regulatory progress was mixed. FDA accepted pivotal milk-residue data and granted zero milk-discard time and zero meat-withhold time, subject to completing analytical-method work. The effectiveness section had received an incomplete letter requesting data clarifications, not new clinical studies; a resubmission was expected in Q4 2011. Target Animal Safety review was pending. The Chemistry, Manufacturing and Controls submission was deferred while partnering and manufacturing-site decisions are considered. FDA approval is not assured.
- A pivotal First Defense rotavirus-formulation study completed in Q3 did not show the anticipated efficacy for approval and market acceptance. The company was analyzing results and conducting pilot studies; positive results could support another pivotal study in 2012.
- Risks include dependence on First Defense and a small number of distributors, dairy-industry economics and feed costs, competition, regulatory and manufacturing delays, and the need to secure acceptable Mast Out funding. The company cites a risk that treated milk could affect some cultured dairy products, although its assessment found negligible risk under label use and normal milk commingling. European regulators are not expected to allow a zero-discard claim.
- Nine-month cash used in operations was partly offset by $600,000 of debt proceeds, option exercises and other financing. Cash declined because of operating use and net purchases of short-term investments; cash plus short-term investments nevertheless increased over year-end. No legal proceedings were reported. Management said disclosure controls were effective and reported no material quarterly change in internal control over financial reporting.
Key facts for investors to verify
- Whether ImmuCell secures Mast Out funding on acceptable terms and can fund the estimated $6 million to $9 million remaining investment.
- FDA responses and timing for Mast Out effectiveness, human-food-safety and target-animal-safety reviews, and the delayed manufacturing submission.
- Whether First Defense sales growth persists, given product and distributor concentration, and whether declining Wipe Out sales continue.
- Cash, short-term investments and covenant headroom relative to the $1 million minimum, alongside continued operating losses and development spending.
- Results of the additional First Defense rotavirus pilot studies and whether they justify another pivotal study.